RNAi Resurgence Continues: Dicerna Closes $60M Series C
In one of the largest private financings for biotech this year, Dicerna Pharmaceuticals Inc. pulled in $60 million in a Series C round to move into the clinic with its lead RNAi-based candidates against genetically defined targets in disease areas such as oncology.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter